Nickolai Malte Kristensen, Frank Viborg Mortensen, Jakob Kirkegård
BACKGROUND: The overall survival of pancreatic cancer (PC) remains low, underlining the need of further research to improve PC directed therapy. Some patients with PC may have experienced a prior cancer, refraining them from inclusion in clinical trials, despite not knowing the precise effect of a prior cancer on disease course of PC. OBJECTIVE: To examine the influence of prior cancer on the disease course in patients with PC. METHODS: We conducted a cohort study including Danish patients diagnosed with PC between 2004 and 2020 crosslinking data from the Danish Cancer Registry, the Danish National Patient Registry among several other databases...
September 19, 2023: Cancer Epidemiology
Anna Najor, Valerie Melson, Junrui Lyu, Priyal Fadadu, Jamie Bakkum-Gamez, Mark Sherman, Andrew Kaunitz, Avonne Connor, Christopher Destephano
OBJECTIVE: We use the person-centered Pathway to Treatment framework to assess the scope of evidence on disparities in endometrial cancer stage at diagnosis. This report is intended to facilitate interventions, research, and advocacy that reduce disparities. DATA SOURCES: We completed a structured search of electronic databases: PubMed, EMBASE, Scopus,, and Cochrane Central Register of Controlled Trials databases. Included studies were published between January 2000 and 2023 and addressed marginalized population(s) in the United States with the ability to develop endometrial cancer and addressed variable(s) outlined in the Pathway to Treatment...
October 1, 2023: Obstetrics and Gynecology
Annika van Oosbree, Lindsay Leigh, Michael Burt, Ryan Garry
Colorectal cancer (CRC) is the third most common cancer to cause death in the world. Despite the recent change in age from 50 to 45 in some societies' recommendations for CRC screening, its incidence is increasing in patients under 50 years. We present a case of a 35-year-old female with no family history of CRC who presented to the emergency department with abdominal pain, vomiting, and obstipation and was found to have sporadic obstructing transverse colon adenocarcinoma.
August 2023: South Dakota Medicine: the Journal of the South Dakota State Medical Association
Yang Liu, Rui Niu, Ruiping Deng, Yinghui Wang, Shuyan Song, Hongjie Zhang
Tumor cells movement and migration are inseparable from the integrity of lipid rafts and the formation of lamellipodia, and lipid rafts are also a prerequisite for the formation of lamellipodia. Therefore, destroying the lipid rafts is an effective strategy to inhibit tumor metastasis. Herein, we developed a multi-enzyme co-expressed nanomedicine: cholesterol oxidase (CHO) loaded Co-PN3 single-atom nanozyme (Co-PN3 SA/CHO) that can up-regulate cellular oxidative stress, disrupt the integrity of lipid rafts, and inhibit lamellipodia formation to induce anti-metastasis tumor therapy...
September 21, 2023: Advanced Materials
Karen Lisa Smith, Hua-Ling Tsai, David Lim, Chenguang Wang, Raquel Nunes, Mary J Wilkinson, Jennifer Y Sheng, Rima Couzi, John Fetting, Carol Riley, Antonio C Wolff, Cesar A Santa-Maria, Katie Papathakis, Lauren Collins-Chase, Christie Hilton, Elissa Thorner, Amanda Montanari, Dara Ikejiani, Claire Snyder, Vered Stearns
PURPOSE: Treatment-associated symptoms drive early discontinuation of adjuvant endocrine therapy (ET) for breast cancer. We hypothesized that symptom monitoring with electronic patient-reported outcomes (ePROs) during adjuvant ET will enhance symptom detection, symptom management, and persistence. METHODS: Eligible patients were initiating ET for stage 0-III breast cancer. Participants completed ePRO surveys via smartphone at baseline and 1, 3, 6, and 12 months...
September 21, 2023: JCO oncology practice
Sun Min Lim, Jii Bum Lee, Yuko Oya, Jorn Nutzinger, Ross Soo
Over the past decade, tremendous efforts have been made in the development of targeted agents in non-small-cell lung cancer (NSCLC) with nonsquamous histology. Pivotal studies have used next-generation sequencing to select the patient population harboring oncogenic driver alterations that are targetable with targeted therapies. As treatment paradigm rapidly evolves for patients with rare oncogene-driven NSCLC, updated comprehensive overview of diagnostic approach and treatment options is paramount in clinical settings...
September 21, 2023: JCO oncology practice
Huma Q Rana, Jill E Stopfer, Michelle Weitz, Lindsay Kipnis, Diane R Koeller, Samantha Culver, Joanna Mercado, Rebecca Sue Gelman, Meghan Underhill-Blazey, Bradley A McGregor, Christopher J Sweeney, Nancie Petrucelli, Courtney Kokenakes, Sara Pirzadeh-Miller, Brian Reys, Arthur Frazier, Andrew Knechtl, Salman Fateh, Donna Rachel Vatnick, Rebecca Silver, Kerry E Kilbridge, Mark M Pomerantz, Xiao X Wei, Atish D Choudhury, Guru P Sonpavde, Olga Kozyreva, Christopher Lathan, Carrie Horton, Jill S Dolinsky, Elisabeth I Heath, Theodora Suzanne Ross, Kevin Dale Courtney, Judy E Garber, Mary-Ellen Taplin
PURPOSE: Germline genetic testing (GT) is recommended for men with prostate cancer (PC), but testing through traditional models is limited. The ProGen study examined a novel model aimed at providing access to GT while promoting education and informed consent. METHODS: Men with potentially lethal PC (metastatic, localized with a Gleason score of ≥8, persistent prostate-specific antigen after local therapy), diagnosis age ≤55 years, previous malignancy, and family history suggestive of a pathogenic variant (PV) and/or at oncologist's discretion were randomly assigned 3:1 to video education (VE) or in-person genetic counseling (GC)...
September 21, 2023: JCO oncology practice
Matea Pavic, Anita Wolfer, Qiyu Li, Arunas Gircys, Stephanie Juritz, Andreas Wicki, Thomas Cerny, Ulrich-Peter Rohr
No abstract text is available yet for this article.
September 21, 2023: Journal of Clinical Oncology
Giulio Francolini, Andrea Gaetano Allegra, Beatrice Detti, Vanessa Di Cataldo, Saverio Caini, Alessio Bruni, Gianluca Ingrosso, Rolando Maria D'Angelillo, Anna Rita Alitto, Matteo Augugliaro, Luca Triggiani, Silvana Parisi, Gaetano Facchini, Marco Banini, Gabriele Simontacchi, Isacco Desideri, Icro Meattini, Richard K Valicenti, Lorenzo Livi
PURPOSE: ARTO ( identifier: NCT03449719) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS: All patients were affected by oligometastatic CRPC as defined as three or less nonvisceral metastatic lesions. Patients were randomly assigned 1:1 to receive either AAP alone (control arm) or AAP with concomitant SBRT to all the sites of disease (experimental arm)...
September 21, 2023: Journal of Clinical Oncology
Deborah B Ejem, Stephen Wechsler, Sarah Gallups, Sarah Khalidi, Jazmine Coffee-Dunning, Aoyjay P Montgomery, Courtney J Stevens, Kimberly Keene, Gabrielle B Rocque, Mary Chamberlin, Mark T Hegel, Andres Azuero, Maria Pisu, Daphne Ellis, Stacey A Ingram, Valerie M Lawhon, Tiffany Gilbert, Kali Morrissette, Jamme Morency, Karen Thorp, Megan Codini, Robin Newman, Jennifer Echols, Danielle Cloyd, Sarah Dos Anjos, Colleen Muse, Susan Goedeken, Kristen Elizabeth Laws, Jennae Herbert, Marie Bakitas, Kathleen D Lyons
PURPOSE: Evidence supporting social media-based recruitment of cancer survivors is limited. This paper describes how we used Facebook during the COVID-19 pandemic to augment our recruitment of breast cancer survivors for our two-site telephone-based randomized clinical trial (RCT) at Dartmouth-Hitchcock Medical Center and the University of Alabama at Birmingham. METHODS: Originally a two-site RCT of a telephone-delivered breast cancer survivorship intervention, we extended our clinic-based recruitment to Facebook...
September 21, 2023: JCO oncology practice
Sergey A Dyshlovoy, Jessica Hauschild, Simone Venz, Christoph Krisp, Katharina Kolbe, Svenja Zapf, Sarina Heinemann, Krystian D Fita, Larisa K Shubina, Tatyana N Makarieva, Alla G Guzii, Tina Rohlfing, Moritz Kaune, Tobias Busenbender, Thomas Mair, Manuela Moritz, Ekaterina V Poverennaya, Hartmut Schlüter, Volodymyr Serdyuk, Valentin A Stonik, Judith Dierlamm, Carsten Bokemeyer, Malte Mohme, Manfred Westphal, Katrin Lamszus, Gunhild von Amsberg, Cecile L Maire
Rhizochalinin (Rhiz) is a recently discovered cytotoxic sphingolipid synthesized from the marine natural compound rhizochalin. Previously, Rhiz demonstrated high in vitro and in vivo efficacy in various cancer models. Here, we report Rhiz to be highly active in human glioblastoma cell lines as well as in patient-derived glioma-stem like neurosphere models. Rhiz counteracted glioblastoma cell proliferation by inducing apoptosis, G2/M-phase cell cycle arrest, and inhibition of autophagy. Proteomic profiling followed by bioinformatic analysis suggested suppression of the Akt pathway as one of the major biological effects of Rhiz...
September 21, 2023: Molecular Pharmaceutics
Syn Kok Yeo, Michael Haas, Kanakaraju Manupati, Mingang Hao, Fuchun Yang, Song Chen, Jun-Lin Guan
Most breast cancers do not respond to immune checkpoint inhibitors and there is an urgent need to identify novel sensitization strategies. Herein, we uncovered that activation of the TBK-IFN pathway that is mediated by the TBK1 adapter protein AZI2 is a potent strategy for this purpose. Our initial observations showed that RB1CC1 depletion leads to accumulation of AZI2, in puncta along with selective macroautophagy/autophagy cargo receptors, which are both required for TBK1 activation. Specifically, disrupting the selective autophagy function of RB1CC1 was sufficient to sustain AZI2 puncta accumulation and TBK1 activation...
September 21, 2023: Autophagy
Zhaochen Ma, Wenjia Chen, Yudong Liu, Lingxiang Yu, Xia Mao, Xiaodong Guo, Funeng Jiang, Qiuyan Guo, Na Lin, Yanqiong Zhang
Sorafenib is the most widely used first-line drug for the treatment of the advanced hepatocellular carcinoma (HCC). Unfortunately, sorafenib resistance often limits its therapeutic efficacy. To evaluate the efficacy of artesunate against sorafenib-resistant HCC and to investigate its underlying pharmacological mechanisms, a "sorafenib resistance related gene-ART candidate target" interaction network was constructed, and a signaling axis consisting with artesunate candidate target AFAP1L2 and sorafenib target SRC, and the downstream FUNDC1-dependent mitophagy was identified as a major contributor to the sorafenib resistance and a potential way of artesunate to mitigate resistance...
September 21, 2023: Autophagy
Tatsuya Hattori, Kevin A Fundora, Kouta Hamamoto, David M Opozda, Xinwen Liang, Xiaoming Liu, Jiawen Zhang, Yasin Uzun, Yoshinori Takahashi, Hong-Gang Wang
The VPS37A gene encodes a subunit of the endosomal sorting complex required for transport (ESCRT)-I complex that is frequently lost in a wide variety of human solid cancers. We have previously demonstrated the role of VPS37A in directing the ESCRT membrane scission machinery to seal the phagophore for autophagosome completion. Here, we report that VPS37A -deficient cells exhibit an accumulation of the apoptotic initiator CASP8 (caspase 8) on the phagophore and are primed to undergo rapid apoptosis through the intracellular death-inducing signaling complex (iDISC)-mediated CASP8 activation upon exposure to endoplasmic reticulum (ER) stress...
September 21, 2023: Autophagy
Cintia Melo Sousa, Izabella Nobre Queiroz, Ana Paula Drummond-Lage
PURPOSE: Assess the local recurrence rate and global survival rate among women diagnosed with breast cancer who underwent intraoperative electron radiotherapy (IOERT) between 2007 and 2017, in a single private healthcare setting in Belo Horizonte, Brazil. MATERIAL AND METHODS: This is a retrospective study based on medical records about the outcomes of patients submitted to breast-conserving surgery followed by IOERT. The collected variables included the patient's profile and tumor features, IOERT isodose, and outcomes...
September 21, 2023: International Journal of Radiation Biology
Zhifei Xu, Zezheng Pan, Ying Jin, Zizheng Gao, Feng Jiang, Huangxi Fu, Xueqin Chen, Xiaochen Zhang, Hao Yan, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Crizotinib, a small-molecule tyrosine kinase inhibitor targeting ALK, MET and ROS1, is the first-line drug for ALK-positive metastatic non-small cell lung cancer and is associated with severe, sometimes fatal, cases of cardiac failure, which increases the risk of mortality. However, the underlying mechanism remains unclear, which causes the lack of therapeutic strategy. We established in vitro and in vivo models for crizotinib-induced cardiotoxicity and found that crizotinib caused left ventricular dysfunction, myocardial injury and pathological remodeling in mice and induced cardiomyocyte apoptosis and mitochondrial injury...
September 21, 2023: Autophagy
Kailash Chandra Mangalhara, Siva Karthik Varanasi, Melissa A Johnson, Mannix J Burns, Gladys R Rojas, Pau B Esparza Moltó, Alva G Sainz, Nimesha Tadepalle, Keene L Abbott, Gaurav Mendiratta, Dan Chen, Yagmur Farsakoglu, Tenzin Kunchok, Filipe Araujo Hoffmann, Bianca Parisi, Mercedes Rincon, Matthew G Vander Heiden, Marcus Bosenberg, Diana C Hargreaves, Susan M Kaech, Gerald S Shadel
Although tumor growth requires the mitochondrial electron transport chain (ETC), the relative contribution of complex I (CI) and complex II (CII), the gatekeepers for initiating electron flow, remains unclear. In this work, we report that the loss of CII, but not that of CI, reduces melanoma tumor growth by increasing antigen presentation and T cell-mediated killing. This is driven by succinate-mediated transcriptional and epigenetic activation of major histocompatibility complex-antigen processing and presentation (MHC-APP) genes independent of interferon signaling...
September 22, 2023: Science
Lestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, Andressa Dias Costa, Matthew H G Katz, Todd W Bauer, Jonathan A Nowak, Brian M Wolpin, Thomas A Abrams, Anuj Patel, Thomas E Clancy, Jiping Wang, Joseph D Mancias, Matthew J Reilley, Chee-Chee H Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Craig L Slingluff, Osama E Rahma, Stephanie K Dougan
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease where bulky tumor burden and limited time to develop anti-tumor T cells may have contributed to poor clinical efficacy. Here we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti-PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors...
September 21, 2023: Clinical Cancer Research
Michael E Stokes, Veronica Calvo, Sho Fujisawa, Crissy Dudgeon, Sharon Huang, Nupur Ballal, Leyi Shen, Jennifer Gasparek, Matthew Betzenhauser, Simon J Taylor, Kirk A Staschke, Alan C Rigby, Mark J Mulvihill, Nandita Bose, Eric S Lightcap, David Surguladze
PURPOSE: Tumors activate protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK, also called EIF2AK3) in response to hypoxia and nutrient deprivation as a stress-mitigation strategy. Here, we tested the hypothesis that inhibiting PERK with HC-5404 enhances the antitumor efficacy of standard-of-care vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKIs). EXPERIMENTAL DESIGN: HC-5404 was characterized as a potent and selective PERK inhibitor, with favorable in vivo properties...
September 21, 2023: Clinical Cancer Research
Larissa G P Langhi Prata, Tamar Tchkonia, James L Kirkland
Cellular senescence is a cell fate caused by multiple stresses. A 2008 article in PLOS Biology reported a senescence-associated secretory phenotype that can promote inflammation and cancer, eventually enabling the development of senolytic drugs.
September 21, 2023: PLoS Biology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.